D4U™ (CHOLECALCIFEROL)

5mg/mL (200,000 IU)
Oral Drops 10mL

Vitamin D_3 analogue

ڈی فور یو (کولی کیلسی فیرول)

اورل ڈراپس ۱۰ ملی لیٹر
۵ ملی گرام/ملی لیٹر (۲۰۰۰۰۰ آئی یو)

DESCRIPTION: Cholecalciferol is the naturally occurring form of Vitamin D, also called Vitamin D3. It is produced from 7- dehydrocholesterol, a sterol present in mammalian skin, by ultraviolet irradiation.
Calciferol is involved in bone fixation of calcium. It is indicated in prevention and treatment of Vitamin D deficiencies.



Chemical Structure

COMPOSITION:

D4U Drops:
Each ml contains:
Cholecalciferol (Vitamin D3) B.P. 5mg

PEDIATRIC DOSE OF DROPS:

Usual Pediatric Dose for Vitamin D Insufficiency:
Treatment of Vitamin D deficiency and/or rickets:
Infants 1 to 12 months: 1000 to 5000 International units/day for 2 to 3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day.
Children older than 12 months: 5000 to 10,000 international units/day for 2 to 3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day.
Prevention and treatment of Vitamin D Deficiency in cystic fibrosis:

Alternate dosing: *Infants less than 1 year:* 8000 international units/week. *Children older than 1 year:* 800 international units/day.
Medium Dose Regimen: *Patients less than 5 years:* 12,000 international units/week for 12 weeks.
Patients 5 years or older: 50,000 international units/week for 12 weeks.

High Dose Regimen: *Patient less than 5 years:* 12,000 international units twice weekly for 12 weeks.
Patient 5 years or older: 50,000 international units twice weekly for 12 weeks.

WARNING & PRECAUTIONS: This drug must not be used in the following cases: Hypersensitivity to any of the ingredients mainly to Vitamin-D. Hypercalcemia (abnormally high blood calcium levels). Hypercalciuria (excessive urinary elimination of calcium). Calcium lithiasis (kidney stones).

CONTRAINDICATIONS: Vitamin D should not be given to patients with hypercalcemia or evidence of Vitamin-D toxicity, Use of Vitamin D in patients with known hypersensitivity to Vitamin D (or drugs of the same class) or any of the inactive ingredient is contraindicated.

Pregnancy and Lactation: This medicinal product can be prescribed during pregnancy or lactation if necessary. However it is preferable to consult your doctor before using this drug.

DRUG INTERACTIONS: Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; as such it may impair intestinal absorption of any of Vitmain-D. **Thiazides:** Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with Vitamin-D causes hypercalcemia, Therefore, precautions should be taken when co-administration is necessary. **Digitalis:** Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias. **Ketoconazole:** Ke-

toconazole may inhibit both synthetic and catabolic enzymes of Vitamin D, Reductions in serum endogenous Vitamin D concentration have been observed following the administration of 300mg/day to 1200mg/day ketoconazole for a week to healthy men. **Corticosteroids:** A relationship of functional antagonism exists between Vitamin D analogues, which promote calcium absorption and corticosteroids, which inhibit calcium absorption. **Phosphate-Binding Agents:** Since Vitamin D also has effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate binding agents must be adjusted in accordance with the serum phosphate concentration. **Vitamin D:** The co-administration of any of the Vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia. **Calcium Supplements:** Uncontrolled intake of additional calcium-containing preparations should be avoided. **Magnesium:** Magnesium-containing preparations (e.g., antacids) may cause hypermagnesemia and should therefore not be taken during therapy with Vitamin D by patients on chronic renal dialysis.

Overdosage: In the event of an overdosage vitamin D3, following symptoms may occur: headache, fatigue, slimming, growth retardation, nausea, vomiting, excess of urines, intense thirst, arterial hypertension. In case of any symptoms inform your doctor immediately.

UNDESIREABLE AND UNPLEASENT EFFECTS: As with any medicine this product may produce unpleasant effects varying severity in some people. Consult your physician if any unwanted or unpleasant effect is observed.
INSTRUCTIONS: Store below 30ºC. Protect from heat & light.
For Injection: Avoid freezing and injection should not be used if container is leaking, solution is cloudy or it contains un-dissolved particles.

PRESENTATION: D4U Oral Drops are available in 10ml amber green bottle & tamper evident dropper.

خوراک : معالج کی ہدایت کے مطابق استعمال کریں۔
ہدایات : ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔
گرمی، روشنی اور نمی سے محفوظ رکھیں۔ تمام دوائیں بچوں کی پہنچ سے دور رکھیں۔

Manufactured by:
Genix Pharma (Pvt.) Ltd.
44,45-B, Korangi Creek Road, Karachi-75190, Pakistan.
UAN: +92-21-111-10-10-11, **Email:** info@genixpharma.com

Marketed by:
Daneen Pharma (Pvt.) Ltd.
27-Sundar Industrial Estate, Sundar Raiwind Road Lahore, Pakistan.
Tel: +92-42-35297781-2, **Email:** info@daneenpharma.com

ISO 9001:2015 ISO 14001:2015 ISO 45001:2018

ISO 9001:2015 ISO 14001:2015 ISO 45001:2018